<DOC>
	<DOCNO>NCT00181740</DOCNO>
	<brief_summary>This open label pilot study Concerta treatment adult diagnosis Attention Deficit Hyperactivity Disorder Not Otherwise Specified ( ADHD NOS ) . We hypothesize ADHD symptomatology adult ADHD NOS responsive Concerta treatment short term Concerta-associated response ADHD symptomatology adult ADHD NOS sustain medium term .</brief_summary>
	<brief_title>Concerta Treatment Adults With ADHD NOS</brief_title>
	<detailed_description>Concerta stimulant medication approve treatment ADHD child . We propose study safety efficacy Concerta therapy adult ADHD NOS . Adult ADHD NOS operationalized either - An adult satisfy current diagnostic criterion ADHD insufficient number childhood symptom fulfill require diagnostic threshold disorder set forth DSM-IV - An adult five current symptom inattention and/or five current symptom impulsivity/hyperactivity , meet full diagnosis criterion six current symptom within one category . Our hypothesis examine two phase open label , pilot study . Phase I study consist six-week acute effectiveness trial . Phase II consist continuation responder subject respond Phase I re-assessed every four week six month . Effectiveness measure improvement clinician-rated scale , include : ADHD Symptom Checklist , Clinical Global Impression : ADHD , Global Assessment Functioning .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Male female outpatient older 18 young 55 year age . 2 . Subjects diagnosis Attention Deficit Hyperactivity Disorder Not Otherwise Specified ( ADHD NOS ) , DSMIV , manifest clinical evaluation confirm structured interview . This operationalized either Having least 5 9 current DSMIV item either inattention hyperactivity/impulsivity &lt; 5 item either list childhood Having 5 9 current DSMIV item either inattention hyperactivity/impulsivity , 6 current symptom either category . This second category include independent presence absence ADHD symptom childhood . 3 . Subjects current Clinical Global Impression : ADHD score 4 ( moderately ill ) high illness severity . 4 . Patients past history depression , bipolar disorder , anxiety disorder ( include OCD ) without current disorder &gt; 3 month ascertain structured diagnostic interview clinical exam . 5 . Subjects treat anxiety disorder depression stable medication regimen least three month , disorder specific CGIseverity score â‰¤ 3 ( mildly ill ) score HamiltonDepression Hamiltonanxiety rating scale 15 ( mild range ) include study . 6 . Subjects past history tic tic free &gt; 1 year . 7 . Subjects past history substance use disorder , substance free &gt; 6 month . 8 . Subjects receive nonMAOI antidepressant ( e.g. , SSRI 's , bupropion , venlafaxine ) , benzodiazepines stable regimen &gt; 3 month condition list . Subjects take SSRIs allow study follow reason : SSRIs know interact methylphenidate Methylphenidate metabolism involve hepatic P450 enzymatic system SSRIs extremely wide margin safety SSRIs methylphenidate combine routinely clinical practice . 9 . Subjects mild case asthma allergy exclude . 10 . Subjects acid reflux syndrome exclude . 11 . Subjects hypercholesterolemia exclude . 1 . Any clinically unstable psychiatric condition include follow : acute psychosis , acute panic , acute OCD , acute mania , acute suicidality , bipolar disorder , acute substance use disorder ( alcohol drug ) , acute OCD , sociopathy , criminality . 2 . Any metabolic , neurological , hepatic , renal , cardiovascular , hematological , opthalmic , endocrine disease . 3 . Clinically significant abnormal baseline laboratory value include follow : Values large 20 % upper range laboratory standard basic metabolic screen . Exclusionary blood pressure parameter include value 140 ( systolic ) 90 ( diastolic ) . Exclusionary ECG parameter include QTC &gt; 460msec , QRS &gt; 120 msec , PR &gt; 200 msec . Subjects ECG evidence ischemia arrhythmia review independent cardiologist . 4 . Mental retardation ( I.Q . &lt; 75 ) . 5 . Organic brain disorder . 6 . Seizures tic last year . 7 . Subjects family history diagnosis Tourette 's syndrome . 8 . Subjects treat monoamine oxidase inhibitor , stop treatment monoamine oxidase inhibitor less 14 day prior baseline visit . 9 . Subjects take coumadin anticoagulant , anticonvulsant , tricyclic antidepressant . 10 . Pregnant nursing female . 11 . Subjects current adequate treatment ADHD history previous adequate trial Concerta . 12 . Non English speaking subject allow study follow reason : The assessment instrument available adequately standardize languages Our clinical trial facility locate Cambridge MGH main campus without availability translator Psychiatric questionnaire evaluation tax add complexity translator potential make patient experience even exhaust .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>ADHD NOS</keyword>
	<keyword>Adults</keyword>
	<keyword>Concerta</keyword>
	<keyword>Open-Label</keyword>
</DOC>